Blue cures blue but be cautious

Blue cures blue but be cautious

Methemoglobinemia is a disorder characterized by the presence of >1% methemoglobin (metHb) in the blood. Spontaneous formation of methemoglobin is normally counteracted by protective enzyme systems, for example, nicotinamide adenine dinucleotide phosphate (NADPH) methemoglobin reductase. Methemog...

Full description

Bibliographic Details
Main Authors: Sikka, Pranav, Bindra, V. K., Kapoor, Seema, Jain, Vivek, Saxena, K. K.
Format: Online
Language:English
Published: Medknow Publications & Media Pvt Ltd 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249703/
id pubmed-3249703
recordtype oai_dc
spelling pubmed-32497032012-01-04 Blue cures blue but be cautious Sikka, Pranav Bindra, V. K. Kapoor, Seema Jain, Vivek Saxena, K. K. Short Communication Methemoglobinemia is a disorder characterized by the presence of >1% methemoglobin (metHb) in the blood. Spontaneous formation of methemoglobin is normally counteracted by protective enzyme systems, for example, nicotinamide adenine dinucleotide phosphate (NADPH) methemoglobin reductase. Methemoglobinemia is treated with supplemental oxygen and methylene blue (1–2 mg/kg) administered slow intravenously, which acts by providing an artificial electron acceptor for NADPH methemoglobin reductase. But known or suspected glucose-6-phosphate dehydrogenase (G6PD) deficiency is a relative contraindication to the use of methylene blue because G6PD is the key enzyme in the formation of NADPH through pentose phosphate pathway and G6PD-deficient individuals generate insufficient NADPH to efficiently reduce methylene blue to leukomethylene blue, which is necessary for the activation of the NADPH-dependent methemoglobin reductase system. So, we should be careful using methylene blue in methemoglobinemia patient before G6PD levels. Medknow Publications & Media Pvt Ltd 2011 /pmc/articles/PMC3249703/ /pubmed/22219589 http://dx.doi.org/10.4103/0975-7406.90112 Text en Copyright: © Journal of Pharmacy and Bioallied Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Sikka, Pranav
Bindra, V. K.
Kapoor, Seema
Jain, Vivek
Saxena, K. K.
spellingShingle Sikka, Pranav
Bindra, V. K.
Kapoor, Seema
Jain, Vivek
Saxena, K. K.
Blue cures blue but be cautious
author_facet Sikka, Pranav
Bindra, V. K.
Kapoor, Seema
Jain, Vivek
Saxena, K. K.
author_sort Sikka, Pranav
title Blue cures blue but be cautious
title_short Blue cures blue but be cautious
title_full Blue cures blue but be cautious
title_fullStr Blue cures blue but be cautious
title_full_unstemmed Blue cures blue but be cautious
title_sort blue cures blue but be cautious
description Methemoglobinemia is a disorder characterized by the presence of >1% methemoglobin (metHb) in the blood. Spontaneous formation of methemoglobin is normally counteracted by protective enzyme systems, for example, nicotinamide adenine dinucleotide phosphate (NADPH) methemoglobin reductase. Methemoglobinemia is treated with supplemental oxygen and methylene blue (1–2 mg/kg) administered slow intravenously, which acts by providing an artificial electron acceptor for NADPH methemoglobin reductase. But known or suspected glucose-6-phosphate dehydrogenase (G6PD) deficiency is a relative contraindication to the use of methylene blue because G6PD is the key enzyme in the formation of NADPH through pentose phosphate pathway and G6PD-deficient individuals generate insufficient NADPH to efficiently reduce methylene blue to leukomethylene blue, which is necessary for the activation of the NADPH-dependent methemoglobin reductase system. So, we should be careful using methylene blue in methemoglobinemia patient before G6PD levels.
publisher Medknow Publications & Media Pvt Ltd
publishDate 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249703/
_version_ 1611497689718980608

Similar Items